Anna P Durbin

Summary

Affiliation: Johns Hopkins Bloomberg School of Public Health
Country: USA

Publications

  1. pmc The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA Electronic address
    Vaccine 31:5772-7. 2013
  2. pmc A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial
    Anna P Durbin
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Rm 217, Baltimore, MD 21205, USA
    J Infect Dis 207:957-65. 2013
  3. pmc Next-generation dengue vaccines: novel strategies currently under development
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Room 251, Baltimore, MD 21205, USA
    Viruses 3:1800-14. 2011
  4. pmc A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    PLoS Negl Trop Dis 5:e1267. 2011
  5. pmc Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States
    Vaccine 29:7242-50. 2011
  6. pmc Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    J Infect Dis 203:327-34. 2011
  7. doi request reprint Dengue vaccine candidates in development
    Anna P Durbin
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
    Curr Top Microbiol Immunol 338:129-43. 2010
  8. doi request reprint Monitoring adverse events following yellow fever vaccination using an integrated telephone and Internet-based system
    Anna P Durbin
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
    Vaccine 27:6143-7. 2009
  9. ncbi request reprint rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    J Infect Dis 191:710-8. 2005
  10. ncbi request reprint rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Hum Vaccin 2:255-60. 2006

Detail Information

Publications23

  1. pmc The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA Electronic address
    Vaccine 31:5772-7. 2013
    ..Based on the encouraging results from these studies, further evaluation of the candidate vaccine in adults older than 50 years of age is planned...
  2. pmc A single dose of any of four different live attenuated tetravalent dengue vaccines is safe and immunogenic in flavivirus-naive adults: a randomized, double-blind clinical trial
    Anna P Durbin
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Rm 217, Baltimore, MD 21205, USA
    J Infect Dis 207:957-65. 2013
    ..Dengue virus (DENV) causes hundreds of millions of infections annually. Four dengue serotypes exist, and previous infection with one serotype increases the likelihood of severe disease with a second, heterotypic DENV infection...
  3. pmc Next-generation dengue vaccines: novel strategies currently under development
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, 624 N Broadway, Room 251, Baltimore, MD 21205, USA
    Viruses 3:1800-14. 2011
    ..These next-generation candidates include DNA vaccines, recombinant adenovirus vectored vaccines, alphavirus replicons, and sub-unit protein vaccines. Several of these novel candidates will be discussed...
  4. pmc A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    PLoS Negl Trop Dis 5:e1267. 2011
    ..The promising safety and immunogenicity profile of this vaccine confirms its suitability for inclusion in a tetravalent dengue vaccine...
  5. pmc Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States
    Vaccine 29:7242-50. 2011
    ....
  6. pmc Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    J Infect Dis 203:327-34. 2011
    ..It remains unclear whether the replication of live attenuated vaccine viruses will be similarly enhanced when administered to Dengue-immune individuals...
  7. doi request reprint Dengue vaccine candidates in development
    Anna P Durbin
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, USA
    Curr Top Microbiol Immunol 338:129-43. 2010
    ..Those DENV vaccine candidates that have been evaluated in preclinical animal models or in clinical trials will be discussed...
  8. doi request reprint Monitoring adverse events following yellow fever vaccination using an integrated telephone and Internet-based system
    Anna P Durbin
    Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States
    Vaccine 27:6143-7. 2009
    ..Participation rates were higher among females and persons older than 60 years of age. TeleWatch can be expanded for use in large campaigns involving influenza or other vaccines...
  9. ncbi request reprint rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland 21205, USA
    J Infect Dis 191:710-8. 2005
    ..The live attenuated dengue virus type 4 (DEN-4) vaccine candidate virus rDEN4 Delta 30 was previously found to be safe and immunogenic at a dose of 10(5) plaque-forming units (pfu)...
  10. ncbi request reprint rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, USA
    Hum Vaccin 2:255-60. 2006
    ..The Delta30 mutation remained unchanged in each isolate, confirming the stability of the Delta30 mutation. Further evaluation of this vaccine in a tetravalent formulation is warranted...
  11. pmc Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever
    Anna P Durbin
    Johns Hopkins Bloomberg School of Public Health, 624 North Broadway, Room 251, Baltimore, MD 21205, USA
    Virology 376:429-35. 2008
    ..Increased activation of monocytes and greater numbers of DEN-infected cells were associated with more severe dengue, implicating a role for monocyte activation in dengue immunopathogenesis...
  12. ncbi request reprint The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Hum Vaccin 2:167-73. 2006
    ..These promising preclinical studies have identified rDEN1Delta30 as a candidate DEN1 vaccine virus for further testing in a human Phase I clinical trial...
  13. pmc Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity
    Julie H McArthur
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
    Am J Trop Med Hyg 79:678-84. 2008
    ..The rDEN4Delta30-200,201 is a promising candidate and can be considered for inclusion in a tetravalent dengue virus (DENV) vaccine...
  14. pmc Emergence potential of sylvatic dengue virus type 4 in the urban transmission cycle is restrained by vaccination and homotypic immunity
    Anna P Durbin
    Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States
    Virology 439:34-41. 2013
    ..These results suggest that emergence of sylvatic strains into the human cycle would be limited by homotypic immunity mediated by virus neutralizing antibodies produced by natural infection or vaccination...
  15. pmc Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naïve adults
    Ruth D Ellis
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases National Institutes of Health, Rockville, Maryland, USA
    PLoS ONE 5:e8787. 2010
    ..To improve the level of antibody response, MSP1(42)-C1 was formulated with Alhydrogel plus the novel adjuvant CPG 7909...
  16. pmc Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria
    Elissa M Malkin
    Johns Hopkins University Bloomberg School of Public Health, Center for Immunization Research, 624 N Broadway, Room 217, Baltimore, MD 21205, USA
    Infect Immun 73:3677-85. 2005
    ..To our knowledge, this is the first AMA1 vaccine candidate to elicit functional immune responses in malaria-naive humans, and our results support the further development of this vaccine...
  17. pmc Evaluation of the Langat/dengue 4 chimeric virus as a live attenuated tick-borne encephalitis vaccine for safety and immunogenicity in healthy adult volunteers
    Peter F Wright
    Department of Pediatrics, Division of Pediatric Infectious Disease, Vanderbilt University Medical Center, Nashville, TN, USA
    Vaccine 26:882-90. 2008
    ..To provide a sufficient level of immunity to widely prevalent, highly neurovirulent strains of TBEV in humans, vaccine candidates will likely need to be based on the TBEV structural protein genes...
  18. ncbi request reprint Development of a live attenuated dengue virus vaccine using reverse genetics
    Joseph E Blaney
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, LID, Bethesda, Maryland 20892 8133, USA
    Viral Immunol 19:10-32. 2006
    ..The level of attenuation of each dengue vaccine component can be increased, if needed, by introduction of additional attenuating mutations that have been well characterized...
  19. ncbi request reprint Prospects for a dengue virus vaccine
    Stephen S Whitehead
    Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nat Rev Microbiol 5:518-28. 2007
    ..In this Review we discuss the unique immunological concerns in dengue virus vaccine development and the current prospects for the development of an acceptable vaccine, a goal that is likely to be reached in the near future...
  20. ncbi request reprint Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria
    Elissa M Malkin
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Twinbrook 1, Room 1123, Rockville, MD 20852, USA
    Vaccine 23:3131-8. 2005
    ..Pvs25H generates transmission blocking immunity in humans against P. vivax demonstrating the potential of this antigen as a component of a transmission blocking vaccine...
  21. pmc Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization
    Steevenson Nelson
    Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 4:e1000060. 2008
    ..Thus, in addition to a role in facilitating viral entry, changes in E protein arrangement associated with maturation modulate neutralization sensitivity and introduce an additional layer of complexity into humoral immunity against WNV...
  22. ncbi request reprint Antigenic relationships between sylvatic and endemic dengue viruses
    Nikos Vasilakis
    Center for Biodefense and Emerging Infectious Diseases, and Department of Pathology, University of Texas Medical Branch, Galveston, Texas 77555 0609, USA
    Am J Trop Med Hyg 79:128-32. 2008
    ..Should a licensed vaccine lead to the eradication of the urban transmission cycle in the future, re-emergence of sylvatic strains into the urban cycle would be limited by homotypic immunity mediated by virus-neutralizing antibodies...
  23. pmc Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51
    Yimin Wu
    Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, United States of America
    PLoS ONE 3:e2636. 2008
    ..This single blinded, dose escalating, controlled Phase 1 study assessed the safety and immunogenicity of recombinant Pfs25 and Pvs25 formulated with Montanide ISA 51, a water-in-oil emulsion...